Increasing Access to Effective Therapies for Atopic Dermatitis
Current strategies used to evaluate the performance of therapies used to treat atopic dermatitis and guide formulary decisions, and recommendations to help patients receive access to effective therapies.
Barriers to Treatment Access in Atopic Dermatitis
Payer and clinician insight regarding access to effective therapies for atopic dermatitis and potential challenges adopting new therapies, including topical JAK inhibitors, into clinical practice.
Unmet Needs in the Treatment of Atopic Dermatitis
An overview of limitations faced by payers and clinicians who play a role in the management of atopic dermatitis.
JAK Inhibitor Treatment Selection for Atopic Dermatitis
Drs Shah and Lio explore where topical ruxolitinib fits into therapeutic sequencing in atopic dermatitis, compared with oral JAK inhibitors.
Building Out Treatment Formularies for Atopic Dermatitis
Variables considered when developing and referring to treatment formularies for atopic dermatitis.
Cost-Benefit Analyses in Atopic Dermatitis
Considerations for quality measures established for atopic dermatitis when assessing how well patients are responding to treatment.
Direct and Indirect Costs of Atopic Dermatitis
Indirect costs associated with atopic dermatitis, and the financial burden associated with delayed treatment initiation or inappropriate therapy.
2 Commerce Drive Cranbury, NJ 08512